Kodai Kunisada - Publications

Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 15, 2026

Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.

Journal: British journal of haematology

Published: January 28, 2026

Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.

Journal: Transplantation and cellular therapy

Published: January 19, 2026

Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: January 06, 2026

Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.

Journal: International journal of hematology

Published: September 27, 2025

Successful management of cardiac arrest due to cytokine release syndrome following chimeric antigen receptor T-cell therapy for multiple myeloma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: September 03, 2025

Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab.

Journal: EJHaem

Published: August 29, 2025

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Journal: Blood advances

Published: May 16, 2025

Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: February 28, 2025

Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: February 09, 2025

Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With Multiple Myeloma Treated With Elranatamab.

Journal: Cureus

Published: December 01, 2024

Local Cytokine Release Syndrome After Idecabtagene Vicleucel Therapy in Patients With Multiple Myeloma: Two Case Reports.

Journal: Cureus

Published: October 25, 2024